anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides a tetomilast crystal that is industrially easily produced in a large volume. (1) a tetomilast hydrate crystal having a powder X-ray diffraction spectrum that is substantially the same as the powder X-ray diffraction spectrum shown in Fig. 2; (2) an anhydrous tetomilast type a crystal having a powder X-ray diffraction spectrum that is substantially the same as the powder X-ray diffraction spectrum shown in Fig. 4; (3) an anhydrous tetomilast type C crystal having a powder X-ray diffraction spectrum that is substantially the same as the powder X-ray diffraction spectrum shown in Fig. 8 ; (4) a tetomilast acetonitrile solvate crystal having a powder X-ray diffraction spectrum that is substantially the same as the powder X-ray diffraction spectrum shown in Fig. 10; and (5) a mixture consisting of the above anhydrous tetomilast type a crystal and an anhydrous tetomilast type B crystal. These crystals are stable towards heat and moisture, and are also excellent in terms of the disintegration property and dissolution property of tablets. Accordingly, these crystals are preferably used as pharmaceutical compositions.
Breast cancer is the most commonly diagnosed cancer among women in the U.S. Approximately 75% to 80% of breast cancer survivors are prescribed HT (hormone therapy) medication for 5 to 10 years following primary treatment. Five years of adjuvant HT among women with non-metastatic cancer reduces the risk of recurrences by 50%. Adherence to HT is also an independent predictor of breast cancer mortality, reducing the risk by up to 28%. HT-side effects, however, are not only a major source of distress but also among the most robust predictors of non-adherence to HT. Therefore, effective management and ability to reduce the burden of these side effects are critically important to achieve optimal HT adherence. Because HT side effects may persist for years and are not easily managed, MBSR's mind-body approach and emphasis on non-judgmental attitudes, acceptance, and uncertainty tolerance may be an especially beneficial approach to helping cancer survivors cope with the burdensome medication-related side effects, thus improving adherence to medication. The investigators propose that a mindfulness-based stress reduction (MBSR) intervention that has been efficacious in reducing HT side effects and improving HRQoL in cancer patients may also prove beneficial in improving HT adherence. After developing a web-based MBSR intervention and refining it via a usability trial, this study will establish the feasibility of a web-delivered, group based MBSR intervention to improve HT medication adherence and HRQoL in patients being treated for breast cancer. It is hypothesized that participants assigned to the MBSR intervention will have better primary outcomes than participants in the control group, which receives standard health information.
Comprehensive whole-body models (WBMs) accounting for organ-specific dynamics have been developed to simulate adult metabolism, but such models do not exist for infants. Here, we present a resource of 360 organ-resolved, sex-specific models of newborn and infant metabolism (infant-WBMs) spanning the first 180 days of life. These infant-WBMs were parameterized to represent the distinct metabolic characteristics of newborns and infants, including nutrition, energy requirements, and thermoregulation. We demonstrate that the predicted infant growth was consistent with the recommendation by the World Health Organization. We assessed the infant-WBMs' reliability and capabilities for personalization by simulating 10,000 newborns based on their blood metabolome and birth weight. Furthermore, the infant-WBMs accurately predicted changes in known biomarkers over time and metabolic responses to treatment strategies for inherited metabolic diseases. The infant-WBM resource holds promise for personalized medicine, as the infant-WBMs could be a first step to digital metabolic twins for newborn and infant metabolism.
Study #3 is made up of five sessions done on five separate days and the entire study can be completed in as little as 14 weeks. All testing sessions will take place at the Exercise Physiology Research Laboratory. Volunteers will be asked to participate in one initial testing session (Visit 1) lasting \< 1 hour that will help make them more familiar with the study equipment and procedures, determine body measures (height, weight, body fat), determine the maximum strength of their forearm and calf, and require one blood draw. The following two testing sessions (Visits 2 and 3) with each session lasting between 2-3 hours that will involve multiple tests designed to determine the health of their blood vessels. For Visit #2 they will be randomly given either antioxidant pills or placebo pills to determine the effect of oxidants on blood vessel health. For Visit #3, they will be given whatever set of pills (antioxidant or placebo) that they did not receive during Visit #2. also include two additional testing days (Visits 5 and 6) that are identical to Visits #2 and #3, two visits to test endurance or strength prior to and after the exercise training (Visit 4 and 7), and ten weeks of exercise training (done 3-5 days per week). The exercise training will include one of two weight lifting programs that differ based on the amount of weight lifted (heavy vs moderate weight).
The invention concerns a method for preparing a modified biodegradable polymer in aqueous medium comprising at least two steps. The first step is a reaction between an amino acid, a peptide or a polypeptide and maleic anhydride to form a compound having an unsaturated vinyl-carboxylic acid function. In the second reaction step, the unsaturated diacid obtained in the first step is reacted with a biodegradable polymer having at least one primary amine function, such as a fibrous protein or a glycosaminoglycan. The preferred polymer used is collagen or chitosan. The invention also concerns the modified biodegradable polymer obtained by the method. The invention further concerns a biomaterial or a dressing containing the modified biodegradable polymer having biocompatible, cytocompatible, hemostatic, bactericidal and wound healing properties, and its medical, biomedical, pharmaceutical or cosmetic use.
PURPOSE:To obtain an aqueous liquid containing a fat-soluble substance, a phospholipid and a polyhydric alcohol and capable of being uniformly emulsified and solubilized by simple and gentle agitation, by using a basic amino acid, its salt and meglumine as essential components. CONSTITUTION:The objective liquid contains a basic amino acid (e.g., L-arginine or L-lysine) and its salt or meglumine. The content of the basic amino acid, its salt and meglumine in the aqueous liquid is preferably 0.1-5.0 pts.wt. per 1 pt.wt. of the phospholipid. The fat-soluble substance is one or more substances selected from vitamin E, vitamin E acetate, coenzyme Q10, vitamin A, etc. The phospholipid is e.g., soybean phospholipid or yolk lecithin and the polyhydric alcohol is e.g., glycerol or D-sorbitol.
For this project, adult patients (\>40 years) undergoing lumbar spinal fusion will be randomized to undergo teriparatide treatment for 1 month prior to surgery. Patients will have their baseline BMD assessed by DEXA scan must be considered as osteoporotic (\>2.5 SD from sex-matched young adult, or previous vertebral and/or femoral fractures) and indicated for spinal fusion surgery to undergo study. Exclusion criteria included Paget disease of bone, high laboratory tests for serum alkaline phosphatase or calcium, previous radiation treatment or fusion surgery to lumbar spine, bone tumors, metabolic bone disease, and hypersensitivity to teriparatide. Surgery involving single- or multi-level lumbar spinal fusion for any of the conditions: lumbar spinal stenosis, degenerative/isthmic/congenital spondylolisthesis, degenerative scoliosis. Only the surgeon and assessors will be blinded as patients will know their treatment arm.

Patients undergo a quantitative CT prior to initiation of teriparatide treatment. After one month of Teriparatide treatment, the drug is discontinued with another DEXA scan to see the changes in BMD. A quantitative CT will be performed after surgery and at 6 months postoperatively. Follow-up schedules include preoperative, immediate postoperative, postoperative 6 weeks, 3 months, 6 months, 12 months and at 24 months. At all follow-up timepoints, any complications, fusion demonstrated by cross-trabeculation on x-rays (with final confirmation at the 6 month CT), and objective questionnaires for quality of life including the EuroQoL 5 dimensions 5-level questionnaire (EQ-5D-5L), back pain numeric rating scale (NRS), osteoporosis assessment questionnaire-physical function (OPAQ-PF) and ambulatory status assessment (ASA) questionnaires will be recorded. Other quality-of-life scores include ODI and SF-36, along with adherence evaluation of osteoporosis treatment (ADEOS), osteoporosis attitude questionnaire and osteoporosis knowledge questionnaire. Once a patient is identified to be suitable for this protocol, they will need to be assessed by a medical social worker to be unable to afford this entire treatment regimen before institutional support for the drug treatment is provided.
Ceftriaxone-calcium precipitates in the gallbladder have been observed in patients receiving ceftriaxone. These precipitates appear on sonography as an echo without acoustical shadowing suggesting sludge or as an echo with acoustical shadowing which may be misinterpreted as gallstones. The probability of such precipitates appears to be greatest in pediatric patients. Patients may be asymptomatic or may develop symptoms of gallbladder disease. The condition appears to be reversible upon discontinuation of ceftriaxone sodium and institution of conservative management. Discontinue ceftriaxone sodium in patients who develop signs and symptoms suggestive of gallbladder disease and/‌or the sonographic findings described above.
The intervention group consists of two parts: children training session and parent group sessions. All children participants will complete a total of 6 training sessions, and each session will last around 90 minutes. Parents of the children participants will also complete a total of 3 group sessions, and each session will last around 90 minutes. Participants will receive intervention in Phase 1.
Healthy, human subjects perform 3 x 30 seconds of supramaximal exercise. Venous blood samples were obtained before and up to 60 minutes after the exercise bout. The blood was used for absolute count of lymphocytes and monocytes per volume blood, and for isolation of CD8+ T cells. It was also used for blood gas analysis. The CD8+ T cells were characterized using flow cytometry, and then cultured for 7 days with CD8+ activation beads. The cells were counted and analyzed for viability at day4 and day8. RNAseq was performed on CD8+ cells isolated before and directly after exercise. CD8+ T cells from Day 1 pre and post exercise and then after 7 days of culture, were analyzed for IFNgamma release using Elispot, and for cytotoxicity against HEK cancer cells in vitro. Flow cytometry of CD8+ T cells was performed on fresh CD8 T cells pre and post exercise, and then on day4 and day8 after culture. SeaHorse metabolic assay was done on Day1 CD8 T cells obtained pre and post exercise.
BACKGROUND: Androgenetic alopecia is the most common cause of hair loss that affects over 50% of the world population. It is a condition that is multifactorial in origin, with no specific causative factor, making treatment an enervating experience for the patient as well as the doctor. In recent times, a number of modalities have been introduced for the treatment of alopecia. However, the evidence supporting them is unstructured and sparse. Therefore, this article aims to explore the current trends in minimally invasive treatments for the management of androgenetic alopecia.
METHODS: An in-depth literature search on injectables used in the treatment of alopecia in PubMed/MEDLINE, Embase, PsycINFO, TRIP Cochrane Library, and Cochrane Skin databases between January 2000 and May 2023 was performed. The studies included were randomized controlled trials, non-randomized trials, quasi trials, single arm interventions, and cohort studies.
RESULTS: Sixteen of the 1071 studies that were found during the original search were accepted in accordance with the inclusion criteria. Twelve studies assessed the effectiveness of the injectable group by comparing it to a control group consisting of saline, distilled water, and topical minoxidil. In the treatment of alopecia, dutasteride and injectable growth factor formulations achieved clinically significant results.
CONCLUSION: The usage of injectables and topical medicines to treat hair loss has increased in the recent years. Overall results from clinical investigations, pilot studies, and trials looking at the efficacy and safety of these growth factors in the AGA show satisfactory efficacy.
Invasive aspergillosis (IA) remains a major cause of morbidity and mortality in immunosuppressed patients. The diagnosis of IA is challenging due to lack of sensitive and specific clinical and radiological signs, and tissue biopsy is often precluded in many patients. Culture and microscopy of respiratory tract samples are relatively insensitive diagnostic tests. Early detection of IA can lead to specific therapeutic strategies and improved patient outcomes. Breath is a rich and complex sampling medium containing both volatile organic compounds (VOCs) and respiratory droplets carrying non-volatiles, proteins, lipids, viruses and even bacteria. The major advantage of exhaled breath analysis is non-invasiveness, with existing sampling methods already readily available.

The diagnostic or prognostic value of exhaled breath analysis has been evaluated in many respiratory diseases, including asthma, Chronic Obstructive Pulmonary Disease, idiopathic pulmonary fibrosis, as well as in some lung infections such as bacterial pneumonia. In the particular field of aspergillosis diagnosis, using a chromatographic-mass spectrometry analysis of exhaled breath in immunocompromised hosts (organ transplantation, hematological malignancies or HSCT), researchers have been able to identify an exhaled breath metabolic signature (made of β-trans-bergamotene, α-trans-bergamotene, a β-vatirenene-like sesquiterpene, and trans-geranylacetone) that potentially allows the discrimination of probable or proven aspergillosis from other lung infections, with high levels of sensitivity and specificity. Exhaled breath therefore appears as a promising field for the improvement of IA diagnosis, and more broadly of respiratory infections. Volatile organic compound (VOC) detection via thermal desorption/gas chromatography-mass spectrometry has emerged as a promising tool for early diagnosis of IA, however the sample sizes have been limited. As such, the proposed pilot study aims to identify potential VOC biomarkers for both IA and Aspergillus colonization and assess the feasibility of VOCs on breath for the diagnosis of IA in lung transplant recipients.
The invention discloses a lactobacillus johnsonii GZ2 and application thereof in high-efficiency synthesis of gamma-aminobutyric acid. The Lactobacillus hilus GZ2 is separated from the Daqu liquor with the preservation number of CGMCC NO.26755. The invention adopts the Lactobacillus johnsonii GZ2 strain, takes lactose as the only carbon source, does not add sodium glutamate, and can produce 230mg/L gamma-aminobutyric acid. Sodium glutamate is used as a substrate, and a multiple fermentation control strategy of acid control-fed-batch glucose carbon source is adopted, so that the capacity of high-yield gamma-aminobutyric acid can be realized, and the cumulative concentration of gamma-aminobutyric acid is 151.7g/L. Lactic acid bacteria products obtained by using lactobacillus johnsonii GZ2, such as dairy products, sour dough, fermented juice and the like, are all internationally recognized safe and healthy foods. The gamma-aminobutyric acid produced by the biological method has no potential safety hazard, and can reach the food safety level.
<P>PROBLEM TO BE SOLVED: To provide an α-keto acid reductase and a method for producing an optically active α-hydroxy acid utilizing the enzyme.  <P>SOLUTION: The α-keto acid reductase is derived from Leuconostoc mesenteroides subsp. dextranicum. A DNA encoding the α-keto acid reductase is isolated. The enzyme and its homolog reduce an α-keto acid in the presence of NADH to produce the optically active α-hydroxy acid. The α-hydroxy acid includes an optically active mandelic acid derivative (formula II). The obtained optically active mandelic acid derivative is useful as an intermediate for synthesizing medicines or agrochemicals.  <P>COPYRIGHT: (C)2004,JPO
Participants randomized to the intervention arm will receive standard care plus an infusion of thawed plasma, starting rate 30 ml/hour for 24 hours, increased to 50 ml/hour if deemed to be hypovolemic (low fluid volume). Only non-convalescent (COVID-antibody-free) plasma will be used.
The invention discloses a nucleic acid nano structure carrier, a nucleic acid nano structure carrier-precious metal photosensitive contrast agent composite comprising the same, and preparation methods and applications of the carrier and the composite. The nucleic acid nano structure is a random two-dimensional and/or three-dimensional nano structure constructed by a DNA paper-folding technology. The precious metal components are used to carry out DNA modification on the surface of the carrier and selected from one or more of gold nano rods, gold nano shells, silver-coated gold nano rods, and gold nano cages. The provided composite is used as a photo-acoustic imaging probe, is capable of guaranteeing the absorption contrast enhancing effect of the photo-acoustic contrast agent which is coupled to the composite, and moreover can prominently improve the targeting performance of the contrast agent on tumors. Furthermore, the precious metal photosensitive components which are coupled to the carrier are enriched in the inner of tumor tissues, and thus the solved is the problems that conventional contrast agent is distributed over the whole human body or the contrast agent can only stay on the tumor surfaces. The preparation method has the advantages of simple technology, low cost, convenience, and easy application.
PROBLEM TO BE SOLVED: To obtain a liquid preparation composition prevented in coloring with time by including minoxidil and an amino acid. SOLUTION: This liquid preparation composition is obtained by including minoxidil and an amino acid, preferably in an amount of 0.01-20 pts.wt. based on 1 pt.wt. minoxidil. The amino acid includes preferably a sulfur-containing amino acid (e.g. taurine, cysteine, cystine or methionine). The solvent for liquid preparation is preferably a mixed solution of 10-50 V/V% water with 1-6C alcohols (preferably ethanol, propylene glycol or 1, 3-butylene glycol. Minoxidil is preferably formulated in an amount of 0.1-5 wt.% based on total preparation. When the liquid preparation is diluted to 20 times with purified water, pH of the diluted solution is preferably 4-9. Container for storing the composition is preferably made of a material such as PET, glass, polyethylene or polypropylene. The liquid preparation can be formulated with a solution auxiliary, a thickener, a absorbefacient, etc.
Suicide attempts involving drug abuse are a major public health problem. Development of interventions that focus on reducing the suicide attempt rate among drug abusers is a necessity. There is a strong connection between drug abuse and both suicide attempts and completed suicide. As much as 45% of drug abusers have attempted suicide at least once. The rate of completed suicide among drug abusers has been reported to be as much as 30 times the rate for the general population. Unfortunately, there is a lack of empirically supported treatments for reducing suicidal behavior in drug abusers. This study will develop and evaluate the effectiveness of a cognitive therapy intervention for people with a drug dependence disorder who recently attempted suicide.

Participants in this single-blind study will be randomly assigned to one of two treatment groups: cognitive therapy combined with enriched usual care; or enriched usual care alone. An initial baseline assessment will occur within 7 days following the participant's suicide attempt and subsequent medical evaluation at a hospital emergency department. Suicide behavior and ideation, depression, hopelessness, and addiction severity will be assessed. Following the baseline assessment, treatment will begin. The cognitive therapy treatment will be specifically developed to prevent suicide attempts. It will involve the identification of proximal thoughts, images, and core beliefs that were activated prior to the suicide attempt. Cognitive and behavioral strategies will be applied to address the identified thoughts and beliefs. Patients will also learn adaptive ways of coping with stressors. The enriched usual care will entail standard treatments for suicide prevention. Study visits will occur 1, 3, 6, 12, 18, and 24 months following enrollment. Baseline measurements will be repeated at each study visit to evaluate participants' improvement. Participants receiving cognitive therapy will attend approximately 10 weekly or bi-weekly outpatient study visits. Participation will last for 2 years.

For information on a related study, please follow this link:

http://clinicaltrials.gov/show/NCT00149773
Participants assigned to the experimental arm will receive the active SMS intervention. Participants in the active intervention group who consent to participate will be asked to complete a web-based survey. Based on survey findings, purposive sampling will be used to select a subsample of 12 to 20 participants for qualitative interviews.
The present invention discloses a medicine for treating ischemic necrosis of a femoral head, which belongs to a Chinese material medical preparation which treats femoral head necrosis and uses Chinese herbal medicines as raw materials. The present invention has the specific scheme that the medicine for treating ischemic necrosis of a femoral head is characterized in that the medicine for treating ischemic necrosis of a femoral head is composed of components in the following portions by weight: 40 to 60 portions of tortoise plastrons, 40 to 60 portions of sanguis draconis, 40 to 60 portions of an antler glue, 40 to 60 portions of pangolins, 40 to 60 portions of hemlock parsley, 40 to 60 portions of Chinese angelica roots, 40 to 60 portions of safflowers and 40 to 60 portions of prepared rehmannia roots. The components are sieved, cleaned, disinfected, dried and pulverized to synthesize the Chinese material medical preparation. The clinical using condition of the medicine for treating ischemic necrosis of a femoral head indicates that the medicine for treating ischemic necrosis of a femoral head, which treats the femoral head necrosis by utilizing the comprehensive action of various traditional Chinese medicines, has little toxic side effect on a human body. No toxic side effect is found through animal experiments. The effectual rate of the medicine for treating ischemic necrosis of a femoral head is proved by 162 clinically tracked cases as 88%, and the effective rate is 92%. The present invention is used for treating the ischemic necrosis of a femoral head.